Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status Japanese depressive patients

Journal of Clinical Psychopharmacology

Volumn 16, Issue 4, 1996, Pages 286-293

  Koyama, Eriko ^a   Tanaka, Takeshi ^b   Chiba, Kan ^a   Kawakatsu, Shinobu ^b   Morinobu, Shigeru ^b   Totsuka, Shirou ^b   Ishizaki, Takashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DESIPRAMINE; IMIPRAMINE; MEPHENYTOIN; METOPROLOL; METOPROLOL TARTRATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HYDROXYLATION; JAPAN; MALE; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; DESIPRAMINE; FEMALE; HUMANS; IMIPRAMINE; JAPAN; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PHENOTYPE;

EID: 0030055999     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199608000-00003     Document Type: Article

References (42)

1. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990;18:346-64.
2. Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In: Meltzer HY, ed. Psychopharmacology: the third generation progress. New York: Raven Press, 1987:1353-63.
3. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977;34:197-204.
4. Reisby N, Gram LF, Bech P. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology 1977;54:363-72.
5. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
6. Brøsen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988;43:400-6.
7. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine phenotype. Clin Pharmacol Ther 1986;40:543-9.
8. Spina E, Arena A, Pisani F. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine. Ther Drug Monit 1987;9:129-33.
9. Spina E, Birgersson C, von Bahr C, Ericsson O, Mellström B, Steiner E, Sjöqvist F. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36:677-82.
10. Brøsen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
11. Wilkinson GR, Guengerich JP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
12. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1994;306:240-5.
13. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
14. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
15. de Morais SF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
16. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
17. Koyama E, Sohn DR, Shin SG, Chiba K, Shin JG, Kim YH, Echizen H, Ishizaki T. Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxylation phenotypes. J Pharmacol Exp Ther 1994; 271:860-7.
18. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4′-hydroxylation in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994;37:237-42.
19. Breyer-Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier-Perey M, Baettig D, Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Phannacol Ther 1992;52:350-8.
20. Skjelbo E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R) ratio - a population study. Br J Clin Phannacol 1993;35:331-4.
21. Madsen H, Kramer Nielsen K, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol 1995;39:433-9.
22. Kramer Nielsen K, Brøsen K, Hansen JMG, Gram LF. Single dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
23. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
24. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, Liao CL, Zhang LM. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
25. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Phannacol 1990;39:533-7.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
27. Horai Y, Taga J, Ishizaki T, Ishikawa K. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol 1990;29: 111-5.
28. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Phannacol Exp Ther 1992;262: 1195-202.
29. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Dapsone N-acetylation, metoprolol α-hydroxylation and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 1994;56:142-53.
30. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989;45: 495-9.
31. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin. Clin Pharmacol Ther 1990;48:286-95.
32. Black C, May G, Csuka ME, Lupoli S, Wilkinson GR, Branch RA. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease. Clin Pharmacol Ther 1992;52: 659-67.
33. Koyama E, Kikuchi Y, Echizen H, Chiba K, Ishizaki T. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics. Ther Drug Monit 1993;15:224-35.
34. Lemoine A, Gautier JC, Azoucy D, Kiffel L, Belloc G, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochrome P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
35. Ohmori S, Takeda S, Kitada M, Rikihisa T, Kikuchi M, Kanakubo Y. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull 1993;16:571-5.
36. Andersson T, Miners JO, Veronese M, Brikett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994;38:131-7.
37. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45: 348-55.
38. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:162-9.
39. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
40. Spina E, Buemi AL, Sanz E, Bertilsson L. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. Ther Drug Monit 1989;11:721-3.
41. Otani K, Nordin C, Bertilsson L. No interaction of diazepam on amitriptyline disposition in depressed patients. Ther Drug Monit 1987;9:120-2.
42. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharniacol 1992;34:256-61.